diet Short Term Fasting / HO-1 Cancer Research Results

dietSTF, diet Short Term Fasting: Click to Expand ⟱
Features:
Short-term fasting (STF) 48 to 72 h before chemotherapy appears to be more effective than intermittent fasting. Preliminary data show that STF is safe but challenging in cancer patients receiving chemotherapy.

Short-Term Fasting (STF; ~24–72 h water / very low calorie fast) Cancer vs Normal Cell Effects
Rank Pathway / Axis Cancer Cells Normal Cells Label Primary Interpretation Notes
1 Insulin / IGF-1 signaling ↓ IGF-1 survival signaling (stress) ↓ IGF-1 with adaptive protection Driver Differential stress resistance (DSR) Cancer cells fail to adapt to acute IGF-1 withdrawal; normal cells enter protective mode
2 AMPK → mTOR nutrient sensing ↑ AMPK; ↓ mTOR (growth crisis) ↑ AMPK; ↓ mTOR (protective quiescence) Driver Catabolic enforcement Rapid mTOR suppression removes anabolic support from tumors
3 Autophagy (ATG program) ↑ autophagy → metabolic exhaustion ↑ autophagy → cytoprotection Driver Catabolic stress vs survival recycling Autophagy is protective in normal cells but destabilizing in cancer cells
4 Mitochondrial metabolism / flexibility ↓ metabolic flexibility; ↓ ATP resilience ↑ mitochondrial efficiency Secondary Energy crisis vs optimization Tumors struggle to switch fuels; normal cells adapt
5 Reactive oxygen species (ROS) ↑ ROS (secondary to energy stress) ↓ ROS Secondary Metabolic redox divergence ROS increase is indirect, arising from metabolic collapse
6 NRF2 antioxidant response ↔ or insufficient activation ↑ NRF2 (protective) Adaptive Stress buffering in normal cells Normal cells activate antioxidant defenses; tumors often cannot
7 Cell cycle / proliferation ↓ proliferation / ↑ arrest ↓ proliferation (protective quiescence) Phenotypic Growth suppression Cell-cycle slowdown reflects upstream nutrient deprivation
8 Therapy sensitivity (chemo / RT) ↑ sensitivity ↓ toxicity Phenotypic Differential stress sensitization STF selectively sensitizes tumors while protecting normal tissue

Fasting Type vs Effectiveness
Fasting Type Definition Primary Metabolic / Signaling Effects Cancer-Relevant Mechanisms Evidence Base Relative Effectiveness*
Caloric Restriction (CR) Chronic daily reduction in total caloric intake (typically 20–40%) without malnutrition. ↓ insulin, ↓ IGF-1, ↓ mTOR, ↑ AMPK, ↑ autophagy Reduces growth signaling; improves metabolic milieu; may slow tumor initiation/growth in models. Extensive animal data; observational human data. Moderate–High
Caloric Restriction Mimetic (CRM) Non-fasting interventions that mimic CR signaling without major calorie reduction. ↓ mTOR, ↑ AMPK, ↑ autophagy; altered acetyl-CoA/epigenetic tone (context-dependent) Replicates key CR pathways while preserving nutrition; potential synergy with therapy (context-specific). Strong mechanistic + preclinical; growing human data. Moderate–High
Intermittent Fasting (IF) Regular cycles of fasting and feeding (e.g., 16:8, 18:6, 20:4). Periodic ↓ insulin/IGF-1; ↑ fat oxidation; mild ketosis (variable) Metabolic stress on tumor cells; improved insulin sensitivity; may modulate inflammation. Good animal data; emerging human data. Moderate
Alternate-Day Fasting (ADF) Alternating 24 h fasting with 24 h ad libitum feeding. Strong oscillations in insulin/glucose/ketones; improved metabolic switching Enhanced metabolic flexibility; may promote normal-cell stress resistance. Animal data strong; limited oncology-specific human data. Moderate–High
Short-Term Fasting (STF) Complete or near-complete fasting for ~24–72 h (often around therapy). Sharp ↓ IGF-1; ↓ glucose; ↑ ketones; ↑ autophagy Differential stress resistance (normal-cell protection) and potential tumor sensitization (context-specific). Strong preclinical; small human trials. High
Fasting-Mimicking Diet (FMD) Low-calorie, low-protein, low-sugar diet for 3–5 days designed to simulate fasting. ↓ IGF-1; ↓ mTOR; ↑ autophagy; partial ketosis Similar benefits to STF with improved tolerability; may enhance therapy response in some contexts. Strong animal; increasing human interventional data. High
Protein Restriction (PR) Reduction in total protein or specific amino acids (e.g., methionine restriction). ↓ IGF-1; ↓ mTORC1; altered amino-acid sensing Targets amino-acid dependencies and growth signaling; may synergize with selected therapies. Strong mechanistic; animal + early human data. Moderate–High
Ketogenic / Very-Low-Carb Diet Diet inducing sustained ketosis without fasting (variable protein content). ↓ glucose; ↓ insulin; ↑ ketones May constrain glycolysis-dependent tumors; effects are heterogeneous by cancer type and context. Mixed animal data; heterogeneous human data. Low–Moderate
Time-Restricted Feeding (TRF) Fixed daily eating window (typically 6–12 h), emphasizing circadian alignment. Circadian stabilization; modest ↓ insulin exposure; partial metabolic switching Improves metabolic control; limited deep autophagy unless fasting is long (≥18–20 h). Early-stage; indirect oncology evidence. Low–Moderate
Water-Only Prolonged Fasting Extended complete fasting (>72 h). Deep ketosis; strong autophagy; high physiological stress Potentially strong tumor stress but higher risk and limited controlled oncology study. Limited / heterogeneous; safety considerations significant. Uncertain / Not Rated 
Notes on Effectiveness Ratings
-High: Consistent preclinical efficacy + mechanistic clarity + early human interventional support
-Moderate–High: Strong biology with partial human validation
-Moderate: Solid rationale but limited oncology-specific human data
-Low–Moderate: Indirect or context-dependent effects
-Uncertain: Insufficient or high-risk evidence base
TRF Pattern Feeding Window Fasting Duration Metabolic Depth Cancer-Relevant Effects
14:10 TRF 10 h eating / 14 h fast 14 h Mild Improves insulin sensitivity; typically minimal autophagy.
16:8 TRF 8 h eating / 16 h fast 16 h Mild–Moderate Reduces daily insulin/IGF-1 exposure; partial metabolic switching.
18:6 TRF 6 h eating / 18 h fast 18 h Moderate Greater fat oxidation; autophagy initiation more likely (variable).
20:4 TRF 4 h eating / 20 h fast 20 h Moderate–High Lower insulin for longer; early ketosis in some individuals; more “fasting-like.”
22:2 TRF 2 h eating / 22 h fast 22 h High (borderline IF) Strong circadian + metabolic stress; limited tolerability for many. 
Circadian Timing (Critical for Cancer Relevance)
Early TRF (eTRF)
-Feeding window: ~07:00–15:00 or 08:00–16:00
-Superior reductions in insulin, glucose AUC, and IGF-1 signaling
-Aligns with PER/CRY, BMAL1, CLOCK oscillations
-More favorable for cancer-relevant metabolic control
Late TRF
-Feeding window: ~12:00–20:00 or later
-Weaker insulin and IGF-1 suppression
-Circadian misalignment may blunt benefits


HO-1, HMOX1: Click to Expand ⟱
Source:
Type:
(Also known as Hsp32 and HMOX1)
HO-1 is the common abbreviation for the protein (heme oxygenase‑1) produced by the HMOX1 gene.
HO-1 is an enzyme that plays a crucial role in various cellular processes, including the breakdown of heme, a toxic molecule. Research has shown that HO-1 is involved in the development and progression of cancer.
-widely regarded as having antioxidant and cytoprotective effects
-The overall activity of HO‑1 helps to reduce the pro‐oxidant load (by degrading free heme, a pro‑oxidant) and to generate molecules (like bilirubin) that can protect cells from oxidative damage

Studies have found that HO-1 is overexpressed in various types of cancer, including lung, breast, colon, and prostate cancer. The overexpression of HO-1 in cancer cells can contribute to their survival and proliferation by:
  Reducing oxidative stress and inflammation
  Promoting angiogenesis (the formation of new blood vessels)
  Inhibiting apoptosis (programmed cell death)
  Enhancing cell migration and invasion
When HO-1 is at a normal level, it mainly exerts an antioxidant effect, and when it is excessively elevated, it causes an accumulation of iron ions.

A proper cellular level of HMOX1 plays an antioxidative function to protect cells from ROS toxicity. However, its overexpression has pro-oxidant effects to induce ferroptosis of cells, which is dependent on intracellular iron accumulation and increased ROS content upon excessive activation of HMOX1.

-Curcumin   Activates the Nrf2 pathway leading to HO‑1 induction; known for its anti‑inflammatory and antioxidant effects.
-Resveratrol  Induces HO‑1 via activation of SIRT1/Nrf2 signaling; exhibits antioxidant and cardioprotective properties.
-Quercetin   Activates Nrf2 and related antioxidant pathways; contributes to anti‑oxidative and anti‑inflammatory responses.
-EGCG     Promotes HO‑1 expression through activation of the Nrf2/ARE pathway; also exhibits anti‑inflammatory and anticancer properties.
-Sulforaphane One of the most potent natural HO‑1 inducers; triggers Nrf2 nuclear translocation and upregulates a battery of phase II detoxifying enzymes.
-Luteolin    Induces HO‑1 via Nrf2 activation; may also exert anti‑inflammatory and neuroprotective effects in various cell models.
-Apigenin   Has been reported to induce HO‑1 expression partly via the MAPK and Nrf2 pathways; also known for anti‑inflammatory and anticancer activities.
Scientific Papers found: Click to Expand⟱
1626- dietSTF,  dietFMD,    When less may be more: calorie restriction and response to cancer therapy
- Review, Var, NA
CRM↑, ChemoSen↑, RadioS↑, eff↑, eff↑, IGF-1↓, TumCG↓, AMPK↑, eff↑, ChemoSen↑, RadioS↑, ROS↑, DNAdam↑, eff↑, HO-1↓,

Showing Research Papers: 1 to 1 of 1

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 1

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress ⓘ

HO-1↓, 1,   ROS↑, 1,  

Core Metabolism/Glycolysis ⓘ

AMPK↑, 1,   CRM↑, 1,  

DNA Damage & Repair ⓘ

DNAdam↑, 1,  

Proliferation, Differentiation & Cell State ⓘ

IGF-1↓, 1,   TumCG↓, 1,  

Drug Metabolism & Resistance ⓘ

ChemoSen↑, 2,   eff↑, 4,   RadioS↑, 2,  
Total Targets: 10

Pathway results for Effect on Normal Cells:


Total Targets: 0

Scientific Paper Hit Count for: HO-1, HMOX1
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:226  Target#:597  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page